Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23732168 | 0.88 | KMT2A (0.45) | KMT2AUSP2MEN1SHMT2THRB | |
| SCHEMBL23732167 | 0.79 | SMN1; SMN2 (0.54) | KMT2ALMNAKDM4EKDM4C | |
| SCHEMBL21408329 | 0.78 | KMT2A (0.67) | KMT2AUSP2 | |
| SCHEMBL23732218 | 0.78 | KMT2A (0.46) | KMT2AUSP2MEN1SHMT2THRB | |
| SCHEMBL23127813 | 0.77 | KMT2A (0.53) | KMT2AUSP2MEN1SHMT2THRB | |
| SCHEMBL23127817 | 0.75 | KMT2A (0.43) | KMT2AUSP2MEN1KDM4EKDM4C | |
| SCHEMBL23732172 | 0.74 | SMN1; SMN2 (0.51) | KMT2AMEN1LMNAKDM4EKDM4C | |
| SCHEMBL69046 | 0.73 | KMT2A (0.69) | KMT2AUSP2KDM4E | |
| SCHEMBL16236824 | 0.73 | KMT2A (0.59) | KMT2AUSP2MEN1THRBLMNA | |
| SCHEMBL10740359 | 0.71 | KMT2A (0.39) | KMT2AUSP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210236463-A1 | beta-LACTAMASE INHIBITOR | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210236463-A1 | beta-LACTAMASE INHIBITOR | MGAM, CMBL, MGAM2 | KMT2A 1387/4885USP2 989/4885MEN1 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.